Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/9/2026
- S&P 500, Nasdaq rise as tech, chipmakers rebound
- Oil prices settle $1 higher after Iran and Israel say they have halted attacks
- Tech stocks gain as Trump mulls government stake in AI companies
- Morgan Stanley’s Wilson calls Friday U.S. selloff a "healthy reset"
- Hedge funds loaded up on equities ahead of sharp Friday drop
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- Exclusive-SpaceX plans to set IPO price at $135 per share, targeting record $75 billion raise, source says
- Salesforce to acquire metering platform M3TER for consumption billing
- Quantum Space to go public via $1.2B SPAC merger
- SpaceX sets $135 price for blockbuster IPO, upending Wall Street convention
Fulcrum Therapeutics Inc. (FULC) Misses Q1 EPS by 1c
May 9, 2022 7:07 AM EDTFulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q1 EPS of ($0.64), $0.01 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $2.59 million versus the consensus estimate of $3.94 million.
For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.
... More